Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Binding affinity to SARS-CoV-2 spike protein at 0.16 to 1.25 uM by SPR analysis
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Binding affinity to SARS-CoV-2 spike protein at 0.16 to 5 uM by SPR analysis
Binding affinity to SARS-CoV-2 spike protein assessed as Kd by SPR analysis
Assay data:2 Active, 2 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Binding affinity to SARS-CoV-2 Spike glycoprotein receptor-binding domain at 1.875 to 50 uM in presence of wallichins C by SPR assay
Binding affinity to SARS-CoV-2 Spike glycoprotein receptor-binding domain at 1.875 to 50 uM in presence of wallichins D by SPR assay
Binding affinity to SARS-CoV-2 Spike glycoprotein receptor-binding domain at 1.875 to 50 uM by SPR assay
Assay data:2 Tested
Binding affinity to SARS-CoV-2 full length Spike glycoprotein at 1.875 to 50 uM by SPR assay
Binding affinity to SARS-CoV-2 spike protein receptor-binding domain assessed as equilibrium dissociation constant by biolayer interferometry assay
Assay data:2 Active, 3 Tested
Binding affinity to SARS-CoV-2 Spike trimer protein by SPR analysis
Assay data:1 Active, 1 Activity ≤ 1 µM, 2 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Competitive inhibition of biotinylated heparin binding to His-tagged wild type SARS-COV-2 spike protein assessed inhibition constant incubated for 300 sec by biolayer interferometry streptavidin sensor based assay
Assay data:1 Active, 1 Tested
Competitive inhibition of biotinylated heparin binding to His-tagged wild type SARS-COV-2 spike protein incubated for 300 sec by biolayer interferometry streptavidin sensor based assay
Competitive inhibition of biotinylated heparin binding to His-tagged wild type SARS-COV-2 spike protein at 50 uM incubated for 300 sec by biolayer interferometry streptavidin sensor based assay
Assay data:2 Active, 6 Tested
Inhibition of SARS-CoV 2 spike glycoprotein
Binding affinity to biotinylated recombinant SARS-COV2 S-RBD by SPR analysis
Binding affinity of SARS-COV2 S-RBD by BLI assay
Assay data:2 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 2 Tested
Inhibition of SARS-COV2 spike protein mediated infection of human ACE2 expressing cells
Assay data:4 Active, 4 Tested
Binding affinity to recombinant SARS-COV2 S-RBD incubated for 5 mins by microscale thermophoresis analysis
Assay data:6 Active, 6 Activity ≤ 1 µM, 6 Tested
Binding affinity to CM5 sensor chip immobilized SARS-CoV-2 spike glycoprotein assessed as dissociation constant by SPR analysis
Assay data:1 Active, 8 Tested
Inhibition of SARS-CoV-2 spike glycoprotein expressed in HEK293T cells transfected with pAAV-CAG-HnCovS-RFP assessed as inhibition of membrane fusion to Huh-7 cells expressing hACE2 measured after 4 hrs by cell-cell fusion based fluorescence assay
Inhibition of SARS-CoV-2 spike glycoprotein expressed in HEK293T cells transfected with pAAV-CAG-HnCovS-RFP assessed as inhibition of membrane fusion to Huh-7 cells expressing hACE2 at 30 uM measured after 4 hrs by cell-cell fusion based fluorescence assay
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on